Stevens Capital Management LP Acquires New Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Stevens Capital Management LP purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 947 shares of the medical research company’s stock, valued at approximately $503,000.

Several other institutional investors have also modified their holdings of the stock. Syon Capital LLC increased its stake in Thermo Fisher Scientific by 59.0% in the 4th quarter. Syon Capital LLC now owns 3,350 shares of the medical research company’s stock valued at $1,778,000 after buying an additional 1,243 shares during the period. Two Point Capital Management Inc. increased its stake in Thermo Fisher Scientific by 0.8% in the 4th quarter. Two Point Capital Management Inc. now owns 11,881 shares of the medical research company’s stock valued at $6,306,000 after buying an additional 90 shares during the period. Meritage Portfolio Management acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $895,000. Roffman Miller Associates Inc. PA increased its stake in Thermo Fisher Scientific by 2.9% in the 4th quarter. Roffman Miller Associates Inc. PA now owns 33,493 shares of the medical research company’s stock valued at $17,778,000 after buying an additional 945 shares during the period. Finally, Lyell Wealth Management LP increased its stake in Thermo Fisher Scientific by 10.6% in the 4th quarter. Lyell Wealth Management LP now owns 27,900 shares of the medical research company’s stock valued at $14,809,000 after buying an additional 2,679 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now owns 1,207 shares of the company’s stock, valued at $660,192.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the sale, the director now owns 1,207 shares of the company’s stock, valued at $660,192.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the sale, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock valued at $28,513,384 over the last 90 days. 0.32% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. upped their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Evercore ISI upped their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Barclays upped their price target on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research note on Thursday. Finally, HSBC upped their price target on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $606.76.

Thermo Fisher Scientific Trading Down 0.9 %

Shares of TMO stock traded down $5.29 during trading hours on Thursday, hitting $572.10. 1,183,964 shares of the company were exchanged, compared to its average volume of 1,563,443. The firm has a market cap of $218.38 billion, a PE ratio of 36.99, a PEG ratio of 2.42 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The firm has a fifty day moving average of $572.61 and a 200 day moving average of $529.06.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Analysts expect that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a $0.39 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.